ARD
Contents
Volume 69 Number Suppl I | ARD January 2010
The Eular Journal
Advances in targeted therapies XI
Preface
i1
i61
Advances in targeted therapies XI
F C Breedveld, J R Kalden, J S Smolen
S E Gabriel
i65
Updated consensus statement on biological agents
for the treatment of rheumatic diseases, 2009
D E Furst, E C Keystone, R Fleischmann, P Mease,
F C Breedveld, J S Smolen, J R Kalden, J Braun,
B Bresnihan, G R Burmester, F De Benedetti, T Dörner,
P Emery, A Gibofsky, A Kavanaugh, B Kirkham,
M H Schiff, J Sieper, N Singer, P L C M Van Riel,
M E Weinblatt, M H Weisman, K Winthrop
Cover image: Part of ‘The Dresden Altar’
by Albrecht Dürer (1471–1528),
Alte Meister Gallerie, Dresden, Germany.
Editor
i67
Papers
Francis Berenbaum
Hans Bijlsma
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes
i30
i72
i77
Disclaimer: ARD is owned and published by BMJ
Publishing Group Ltd (a wholly owned subsidiary of
the British Medical Association) and the European
League Against Rheumatism. The owners grant
editorial freedom to the Editor of ARD. ARD follows
guidelines on editorial independence produced by
the World Association of Medical Editors and the
code on good publication practice of the Committee
on Publication Ethics.
ARD is intended for medical professionals and is
provided without warranty, express or implied.
Statements in the journal are the responsibility of their
authors and advertisers and not authors’ institutions,
the BMJ Publishing Group, the European League
Against Rheumatism or the BMA unless otherwise
specified or determined by law. Acceptance of
advertising does not imply endorsement.
To the fullest extent permitted by law, the BMJ
Publishing Group shall not be liable for any loss, injury
or damage resulting from the use of ARD or any
information in it whether based on contract, tort, or
otherwise. Readers are advised to verify any
information they choose to rely on.
Copyright: E 2010 BMJ Publishing Group and
European League Against Rheumatism. All rights
reserved; no partof thispublicationmay bereproduced,
stored in a retrieval system, or transmitted in any form
orbyanymeans,electronic,mechanical,photocopying,
recording, or otherwise without prior permission
ARD is published by BMJ Publishing Group Ltd,
typeset by The Charlesworth Group and printed in the
UK on acid-free paper from sustainable forests by
Cambrian Printers Limited, Aberystwyth, UK
Annals of the Rheumatic Diseases (ISSN No: 00034967) is published monthly by BMJ Publishing
Group and distributed in the USA by Mercury
International Ltd. Periodicals postage paid at
Rahway, NJ, USA. POSTMASTER: send address
changes to Annals of the Rheumatic Diseases,
Mercury International Ltd, 365 Blair Road, Avenel,
NJ 07001, USA.
i43
i48
i83
Role of interleukin 33 in human immunopathology
Bone development and inflammatory disease is
regulated by AP-1 (Fos/Jun)
G E J Murphy, D Xu, F Y Liew, I B McInnes
E F Wagner
Tyrosine kinase inhibitors for the treatment of
fibrotic diseases such as systemic sclerosis:
towards molecular targeted therapies
i86
i89
What are the new milestones in the pathogenesis
of systemic sclerosis?
Inflammation, vascular injury and repair in
rheumatoid arthritis
A J van Zonneveld, H C de Boer, E P van der Veer,
T J Rabelink
The value of productivity: human-capital versus
friction-cost method
W B van den Hout
i92
N Hunzelmann, J Brinckmann
i57
The role of cell–substrate interaction in
regulating osteoclast activation: potential
implications in targeting bone loss in
rheumatoid arthritis
K P McHugh, Z Shen, T N Crotti, M R Flannery,
R P O’Sullivan, P E Purdue, S R Goldring
J H W Distler, O Distler
i52
‘‘Go upstream, young man’’: lessons learned from
the p38 saga
D Hammaker, G S Firestein
Does gene expression analysis inform us in
rheumatoid arthritis?
T Häupl, B Stuhlmüller, A Grützkau, A Radbruch,
G-R Burmester
Can we prevent immunogenicity of human protein
drugs?
D W Scott, A S De Groot
X Luo, L M Tsai, N Shen, D Yu
i37
Editorial office
Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WCIH 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 7.188
Evidence for microRNA-mediated regulation in
rheumatic diseases
XBP1: the last two decades
L H Glimcher
Tore K Kvien
Associate Editors
Treg and lupus
M Bonelli, J S Smolen, C Scheinecker
Consensus statement
i2
Heart disease and rheumatoid arthritis:
understanding the risks
The pro and anti-inflammatory activities of
immunoglobulin G
A Lux, S Aschermann, M Biburger, F Nimmerjahn
i97
What have we learnt from targeted anti-TNF
therapy?
M Feldmann, R O Williams, E Paleolog